Glador 2 Tablet contains Glimepiride 2mg, an oral hypoglycemic agent belonging to the sulfonylurea class, indicated for the management of type 2 diabetes mellitus. It functions by stimulating pancreatic beta cells to release insulin, thereby improving glycemic control in patients with inadequate response to diet and exercise alone. Glimepiride enhances insulin secretion in a glucose-dependent manner, minimizing the risk of hypoglycemia compared to older sulfonylureas. This medication is typically prescribed as part of a comprehensive diabetes management plan, including diet modification, exercise, and regular blood glucose monitoring. Glador 2 Tablet is administered once daily, preferably with breakfast or the first main meal, to optimize efficacy and reduce gastrointestinal discomfort. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, or known hypersensitivity to sulfonylureas. Caution is advised in patients with hepatic or renal impairment, as dose adjustments may be necessary. Common adverse effects include hypoglycemia, weight gain, and gastrointestinal disturbances such as nausea or abdominal discomfort. Patients should be educated on recognizing hypoglycemia symptoms and appropriate corrective measures. Regular monitoring of blood glucose and HbA1c levels is essential to assess therapeutic response and adjust dosage accordingly. Glador 2 Tablet should be used under medical supervision to ensure safe and effective diabetes management.